SlideShare ist ein Scribd-Unternehmen logo
1 von 29
Downloaden Sie, um offline zu lesen
Therapeutic Cancer
Vaccines
A Future of Possibilities Haunted by a History of Failures
Preparedby2911Advisers
Therapeutic CancerVaccines-The Genesis
 Over a century ago, Dr.William B. Coley, a bone surgeon,
developed a method of immunotherapy
 Believing that bacterial toxins stimulated the immune system, he
injected a cancer patient with live bacteria; the patient made a
complete recovery1,2
 Dr. Coley went on to develop a safe and effective mixture of bacteria
for treating cancer patients known as Coley’s mixed bacterial toxins
 Through the decades followingColey’s introduction of
immunotherapy, many attempts have been made to develop and
bring cancer vaccines to market
 Success, however, has been elusive
Prepared by 2911 Advisers
1American Cancer Society
2 www.cancerresearch.org/about/history
Therapeutic CancerVaccines
 Therapeutic cancer vaccines, orTCVs, as with the whole of
immunotherapy, hold a tremendous amount of promise
 Some of that promise has already been realized in several approved
immunotherapeutics, but only oneTCV
 The pipeline for biologics is robust
 PhRMA reports over 900 biologics in development in 15 different
therapeutic areas, targeting a wide range of indications1
 Cancer vaccines comprise nearly 36% of all biologic vaccines in
development in the report2 and 28% of all cancer biologics being
developed
 Preventative cancer vaccines are included in the report
 These slides focus only onTCVs
Prepared by 2911 Advisers
1 PhRMA 2013 Medicines in Development: Biologics
2Trials for 3 vaccines have been stopped and a product acquisition has lowered the reported number
Therapeutic Cancer
Vaccines
Possibilities and Promises in Development
Preparedby2911Advisers
TCVs in Development
 One hundredTCVs are included in this review
 These include most of the vaccines in the PhRMA report, and those
identified through searches on clinicaltrials.gov, the InternationalTrials
Registry, and company pipelines
 New and/or discontinued indications were identified during the
searches of company pipelines
 Trials conducted by the NCI and other agencies, research centers and
universities are not included, unless the trial is being conducted on
behalf of a company
 A 2011 University of Michigan found that there were 231TCVs in
clinical development1; a more recent report2 shows 196TCVs being
developed
Prepared by 2911 Advisers
1 HumVaccin. 2011 Nov;7(11):1124-9
2 Kaloroma
A Snapshot
 Among the 100TCVs, a total of 34 different cancer indications are
targeted
 Ten indications have received orphan designation, 6 received fast track
designation, and 4 were designated both orphan and fast track
 There are 12 specific types of vaccines, i.e. dendritic cell, among the
100 in development
 Twenty-six of the vaccines are in Phase 3 clinical trials
 Four of these trials have been completed, of which two missed their
primary endpoints: Merck KGaA/Oncothyreon (NSCLC) and Kael-GemVax
(pancreatic)
 Seventy-three companies are represented
Prepared by 2911 Advisers
Targeted Indications andTypes ofTCVs
Indication Number
Prostate 16
Breast 15
Glioblastoma 14
NSCLC 12
Melanoma 12
Solid tumors 10
Hematological 10
Type Number
Peptide 20
Genetically-
modified
14
Dendritic 12
Cell
(autologous/alloge
nic)
12
mAB 9
Recombinant 8
Prepared by 2911 Advisers
Other targeted cancers are renal,
SCLC, sarcoma, endometrial, ovarian, colorectal,GI,
pancreatic, bladder, head & neck, colon, urogenital, and
mesothelioma
Other types of vaccines include DNA,
virus vector, virus replicon virus, antibody,
bacterial and polyclonal antibody
TCVs by Clinical Stage
The vaccines in development are shown by their respective
clinical stage in the table below. Note that none are in
regulatory review
Prepared by 2911 Advisers
Stage Number
Phase 0 3
Phase I 28
Phase II 34
Phase III 26
Phase I/II 31
Phase II/III 3
Clinical stage includes recruiting, ongoing, ongoing and recruiting, ongoing but not recruiting
Phase 1, 2 or 3 ready and completed.Trials with an unknown status are not included.
Companies DevelopingTCVs
Activartis Biotech (1) Bioven Europe (1) Endocyte (1)
Adamis Pharmaceuticals (1) Biovest International (1) Etubics (1)
Aduro Biotech (5) B-MS/Medarex (1) Galena Biopharma (2)
Advaxis (1) BN ImmunoTherapeutics (3) Gliknik (1)
Agenus (3) Cancer Advances (1) GlobeImmune (3)
AlphaVax (2) CelldexTherapeutics (2) Gradalis (1)
Antigen Express (2) CGTherapeutics (1) Grupo Insud (1)
ArgosTherapeutics (1) Colby Pharmaceuticals (2) GSK (3)
AvaxTechnologies (2) Dendreon (2) Heat Biologics (1)
Bayer (1) DCPrime (1) Hemispherex (1)
Bellicum Pharmaceuticals (1) EMD Millipore (1) Immatics biotech (2)
BioCancell Ltd (1) EMD/Oncothyreon (1) Immunicum AB (1)
Companies DevelopingTCVs
Immunitor (1) Merck/Vical (1) PsiOxus (1)
ImmunoCellular (1) Mologen AG (1) Stemline Therapeutics (1)
Immunocore (1) NewLink Genetics (3) Sunovion (1)
ImmunoFrontier (1) Northwest Bio (1) Tapimmune (1)
Immunotope (1) NovaRx (2) Transgene/Novartis (1)
Immunovaccine (2) OncoPep (1) Tvax Biomedical (2)
ImmunovativeTherapies (1) Oncothyreon (1) UbiVac (1)
Inovio Pharmaceuticals (1) Onyvax (1) Vaccinogen (1)
Kael-GemVax (1) Optimer Biotech (1) Vaxil Bio (1)
MabVaxTherapeutics (6) PiqueTherapeutics (1) Vaximm GmbH (1)
Mediolanum Farmaceutici (1) Polynoma (1)
Memgen (1) Prima BioMed (1)
Therapeutic Cancer
Vaccines
A History of Development Failures, but Paradigms are Changing
Preparedby2911Advisers
TCVs-Long on Promises………….
Cancer vaccines targeted by many as
the ‘holy grail’ for tumors
Promising CancerVaccineCould
ShrinkTumors By 80 Percent
Brain CancerVaccine Promising
Prostate CancerVaccine Looks
Promising in EarlyTrial
Personalized Immunotherapy Shows
Promise in Mantle Cell Lymphoma
PANVAC for breast, ovarian cancer
shows early promise
Surgical Oncologist Presents
Promising Data for Novel Pancreatic
CancerVaccine
CouldThis BeThe End Of Cancer?
…scientists say vaccines could hold
the key—not just to a cure but to
wiping out cancer forever
Therapeutic polyvalent vaccine
shows promise against melanoma
MUC1 peptide vaccines still show
promise for lung cancer victims
Prepared by 2911 Advisers
Consider these headlines
………..But Short on Approvals
 The preceding headlines come from press releases issued by
companies either developingTCVs while some represent to failed
TCVs
 And whileTCVs and their promises continue to excite physicians,
patients, investors, scientists and analysts
 a speaker at ASCO 2013 reminded his audience that the promises of
immunotherapy extend back at least 40 years, displaying the March 19,
1973 cover ofTime Magazine featuring noted immunologist Robert
Good
 Although new types ofTCVs are in clinical trials including, antigen,
dendritic cell, vector-based, DNA and tumor cell and show positive
results, Provenge remains the only FDA-approvedTCV and none
are approved in the EU
Prepared by 2911 Advisers
Failure Is Not An Option
 The path to approval is littered with failures; Phase 2 vaccines that have
shown great promise fail in Phase 3; below are some examples
Prepared by 2911 Advisers
Biopharmaceutical companies with failed cancer vaccines
Genzyme: Melan-A Genitope: MyVax
Imclone: Mitumomab IDM Pharma: UVIDEM and COLLIDEM
Titan Pharmaceuticals: CeaVac Therion: PANVAC-VF
TeloVac: GV1001 CancerVax: Canvaxin
Corixa: Melacine Oncothyreon/Merck KGaA: Stimuvax*
Oxford Biomedica: TroVax Cell Genesys: GVAX prostate
*Despite missing its primary Phase 3 endpoint for NSCLC, the companies decided to proceed with an ongoing
late-phase trial in Asia and is weighing the options of starting a further study. A decision, partly dependent on
the outcome of talks with regulators, is expected this year.
Some Failures Get a Second Chance
 PROSTVAC failed to demonstrate a reducedTTP for prostate
cancer
 Two years later, it was discovered that PROSTVAC had demonstrated a
statistically significantOS; Bavarian Nordic licensed the drug, which is
now in Phase 3
 Aduro Biotech resurrected twoTCVs it acquired, one for metastatic
pancreatic cancer, now in Phase 2, and the second for prostate
cancer (preclinical)
Prepared by 2911 Advisers
Why DoTCVs Fail?
 A recently published paper suggested that someTCV failures can be
blamed on a self-sabotaging adjuvant1; instead of destroying tumors,
T-cells accumulate at the vaccination site, with the miss-targeting due
to incomplete Freund's adjuvant
 Trial design: selection of clinical trial endpoints, disease stage, patient
population, and trial duration2
 A retrospective analysis of 23 completed or terminated P3 studies
showed that 74% (17/23) failed to demonstrate significant efficacy in
the primary endpoint, suggesting tumor burden may not be the only
prognostic factor3
 Considering the above, the current oncology drug development
paradigm doesn’t fit
Prepared by 2911 Advisers
1 Nature Medicine:Willem Overwijk,Assistant Professor, MD AndersonCancer Center
2 http://obroncology.com/documents/OBR_JAN10_CV.pdf
3 www.landesbioscience.com/journals/vaccines/article/23917/
It’s Not a One-Size-Fits-All Development
Paradigm
Conventional Oncology Drug Development Paradigm, designed for cytotoxics
Phase N (variable) Purpose
1 20 to 80 healthy
volunteers, or patients
(may or may not have
target disease)
Determine safety, dose
range, MTD, DLT
Characterize pK If mixed
population, find target
2 100 to 300 patient
volunteers with targeted
disease
Evaluate effectiveness, look
for side effects. May
provide estimate of effect
size for Phase 3
Discuss continuation with regulatory authorities
3 500 to 1,000 patient
volunteers
Verify effectiveness,
monitor adverse reactions
from long- term use
4 Large number of patients Post-marketing surveillance
Prepared by 2911 AdvisersModified from CheneyT. & Kaspar P. Overview of Clinical Research, 1996.
The Conventional Paradigm Doesn’t Fit:
TCVs Are Not Cytotoxics
Prepared by 2911 Advisers
General principles of oncology drug
development
Why these principles don’t adapt to
cancer vaccines
Increasing dose increases efficacy MTDs aren’t optimal doses; cancer vaccines
usually have low toxicity; no proof for a linear
dose-potency relationship
PK is relevant for finding optimal dose Cancer vaccines aren’t metabolized; not evident
that a MTD will be coincident with the optimal
dose to reach the vaccine effect
Objective responses (OR) predict clinical benefit OR is not a good predictor of survival
Endpoints based on selected tumor size Tumors may progress prior to immune response
and regression
Mixed tumor trials for target selection Many cancer vaccines are designed to address
only one tumor type
Objective progression is considered a failure;
drugs aren’t active if tumor is growing
Cancer vaccines could be actives beyond
disease progression; translating immune
response into antitumor response takes time
Changing the Paradigm
 Over the course of a year, the CancerVaccineClinicalTrialWorking
Group, comprised of more than 50 individuals from academia, the
pharmaceutical and biotech industries, and regulatory bodies
developed and proposed changes to the existing paradigm1
 The Cancer Immunotherapy Consortium of the Cancer Research
Institute, from 2004 to 2009, evaluated an immunotherapy-focused
development paradigm, creating principles for redefining trial
endpoints2
 Other scientists, researchers, regulatory officials and academicians
reviewed the current paradigm and proposed changes3
Prepared by 2911 Advisers
1The CancerVaccine ClinicalTrialWorking Group, J Immunother Jan 2006
2 JNCI J Natl Cancer Inst,Vol 102, Issue 18 Pp. 1388-1397
3 Cancer vaccines:Will we ever learn? Expert Review of AnticancerTherapy, January 2009,Vol. 9, no. 1, Pages 67-74
Recommendations for a New Paradigm:The
CancerVaccineClinicalTrialWorking Group
Prepared by 2911 Advisers
Phase of development Purpose Endpoints
Proof-of-Principle
-N>20
-Defined patient population with
no end stage
-No mandate to investigate exact
mechanism of action disease
-Safety database initiated
-Establish immunogenicity,
biologic activity, clinical activity
-Use established and reproducible
immune assays
-Cohort design determines dose
and schedule of vaccination
-Impact of the vaccine on immune
response or on investigated disease
-Sequential samples for assays
-No mandate to demonstrate
clinical activity with conventional
endpoints
Phase 2 comparative randomized,
powered for statistically significant
difference between two arms in a
well-defined population,
a well-defined primary outcome
measure (may be a surrogate)
-Expansion of safety database
-Establishment of efficacy
-Flexibility of development, e.g.
allow for sample size re-
calculation, allow for modification
of Phase 3 eligibility criteria
-Validated surrogates or
biomarkers as efficacy endpoints
-Validation needs proof-of-
correlation between outcome and
biological marker in single-arm or
randomized studies (prognostic
factor), or
-needs randomized trial showing
that intervention-induced
surrogate correlates with outcome
(immune response)
Phase 3 conventional trial
-Data from Phase 3 component not
to be pooled with Phase 2 data
www.sitcancer.org/meetings/am05/workshop_presentations/workstream_2.pdf, not all recommendations included
Recommendations for a New Paradigm:
The Cancer Immunotherapy Consortium
Prepared by 2911 Advisers
Source: JNCI J Natl Cancer Inst,Vol 102, Issue 18 Pp. 1388-1397
Endpoint Cellular immune response Antitumor response Survival
Challenges -Complex assays exist
-Results are highly
variable and not
reproducible across trials
-Assay procedures are not
harmonized
-Conventional and novel
response patterns are
observed
-Translating immune
response into antitumor
response takes time
-No systematic criteria to
capture new response
patterns exist
-Time it takes to translate
immune and antitumor
response into a survival
effect
-Conventional statistical
models don’t account for
non-proportional hazards
and delayed separation of
curves
Recommendations -Harmonized assay use
through SOPs that
accompany individual
assay protocols
-Identify relevant
response patterns
-Use systematic criteria
(irRC*) to reproducibly
capture new patterns
-Employ statistical
models that account for
the delayed effect
-Carefully consider use of
early interim and futility
analyses
The core aspects of all recommendations are included in Guidance for Industry:ClinicalConsiderations forTherapeuticCancerVaccines
US Dept. of Health and Human Services, FDA,CBER, October 2011
* immune-related response criteria
Regulatory Comments and
Considerations
May or may not determine MTD
(and that’s OK)
Vaccine-specific toxicities as
endpoint for early stage trials-
clinical activity is secondary
objective
Explore continuation of vaccine after
initial progression if
Subject continues to meet
eligibility criteria
No clinical deterioration
No curative salvage therapy
exists
Consider randomized Phase 2 trials
PFS,TTP, DFS can’t be
interpreted in single arm trials
Single arm trials may lead to
overly optimistic interpretation
of effect size
Phase 3 endpoints
PFS is preferred overTTP
OS remains the gold standard
and may be the bestTCV
endpoint as PFS has yet to be
successful
DFS in adjuvant setting
US Regulatory Considerations forTherapeutic Cancer Vaccines
Peter Bross, MD,Team Leader,Clinical Oncology, FDA CBER;2012 AACR Annual Meeting
CBER: Going Beyond Comments and
Considerations
 CBER included the core aspects of a number of the recommendations made by
theCancerVaccine ClinicalTrialWorking Group and the Cancer Immunotherapy
Consortium in a 2011 guidance document1
 Support of virology, molecular and tumor biology, and safety and efficacy
immunology studies of gene transfer and tumor vaccines has begun2,3
 Improved tools for clinical trial and design are being developed
 The division is evaluating and implementing novel methods to improve
reliability, sensitivity, and specificity of assays for product development and lot
release
 CBER acknowledges that endpoints based on tumor assessments4 may not be
appropriate endpoints for a late phase clinical trial for a cancer vaccine
Prepared by 2911 Advisers
1 Guidance for Industry:Clinical Considerations forTherapeuticCancerVaccines,Oct 2011
2 Nat Med 2013 Apr;19(4):452-7,Coagulation factor X shields adenovirus type 5 from attack by
natural antibodies and complement. Xu Z,Qiu Q,Tian J, Smith JS, Conenello GM, MoritaT, Byrnes AP
3 CBER Strategic Plan for Regulatory Science and Research FY 2012-2016; Draft
4 Guidance for Industry:ClinicalTrial Endpoints for the Approval of Cancer Drugs and Biologics; May 2007
The Business ofTherapeutic
CancerVaccines
Deals,Terms and Partnering
Selected Deals andTerms-FailedTCVs
Licensee/Licensor Date Assets Terms
Sanofi
Aventis/Oxford
Biomedica
03/07 TroVax, renal cancer;
Phase 2
WW license; $38.6M upfront, $25.3M
development milestone; total deal
value $690M
SanofiAventis/IDM
Pharma
07/01 UVIDEM, melanoma
Phase 2
WW license; up to $545M
MerckSerono/Canva
x
12/04 Canvaxin, melanoma License; $25M upfront, $12M in
equity, up to $253M in milestones
Takeda/CellGenesys 03/08 GVAX prostate, Phase
3
AcquiredWW rights; $50M upfront,
up to $270M in milestones, tiered
double-digit royalties on net sales in
US, flat double-digit RoW
Selected Deals andTerms-TCVs in
Development
Licensee/Licensor Date Assets Terms
Aduro
Biotech/BioSante
Pharma
04/11 GVAX pancreas,
prostate vaccines
Phase 2 & Phase 3
License; milestones, royalties when
commercialized
02/13 All GVAX vaccines;
Phase 1, Phase 2
and Phase 3
Acquisition; $1M upfront, additional
milestones & royalties when
commercialized
Merck/Vical 06/05 Non-viral gene
delivery technology
Exercised 3 options to licenseVical
technology forTCVs; $3M upfront,
milestones, royalties
Accentia/Biovest 04/03 Biovax ID; Phase 3 $20M equity (81% stake)
Pfizer/Celldex
(Pfizer returned
rights in 2010)
04/08 Peptide vaccine,
glioma; Phase 2
WW license; $40M upfront, $10M
equity, over $390M in milestones,
royalties, fund development
Selected Deals andTerms-TCVs in
Development
Licensee/Licensor Date Assets/Phase Terms
Private
investor/Argos
Therapeutics
11/08 Dendritic cell
vaccine; Phase 1/2
$35.2M Series C financing
Merck KGaA/Biomira
(nowOncothyreon)
05/01 Stimuvax &
Theratope vaccines
WW license; $33.5M in upfront and
equity, share development costs, 50/50
sales split in US, Canada, royalties
elsewhere
01.06 Stimuvax; Phase 3 Acquisition of full US rights; royalties
and regulatory milestones
12/08 Manufacturing;
Phase 3
License/acquisition; $13M to license
mfg. rights and acquire mfg. assets for
Stimuvax
Novartis/Transgene 03/10 Genetically-
modified vaccine;
Phase 2
Option toWW rights; $10M upfront,
additional $950M if option exercised
PartneringTCVs in Development
 There are 5 partnerships identified among the 73 companies in this
review
 B-MS/Medarex (B-MS has acquired Medarex)
 Merck KgaA/Oncothyreon
 Merck/Vical
 Transgene/Novartis
 GlobeImmune/Celgene (Celgene has an exclusive option to license all
of GlobeImmune’s oncology programs)
 A review of the partnering strategies of the remaining companies
reveals at least 44 are or will be seeking a commercialization
partner
About 2911 Advisers
2911 Advisers is a Life Sciences consulting firm in Nashua, NH
and is owned by Michael Sheckler, MBA.With a focus on
oncology and pain management, he assists clients with
business/strategy development, product & technological
assessment, opportunity identification, market valuation,
market/competitive analysis and negotiating licenses.
He can be reached at 603 809-9936 or at
michael.sheckler@gmail.com.
Prepared by 2911 Advisers

Weitere ähnliche Inhalte

Was ist angesagt?

Cancer immunotherapy different modes of action - astra zeneca - jordan
Cancer immunotherapy   different modes of action - astra zeneca - jordanCancer immunotherapy   different modes of action - astra zeneca - jordan
Cancer immunotherapy different modes of action - astra zeneca - jordanMohamed Abdulla
 
Cancer therapy via vaccine
Cancer therapy via vaccineCancer therapy via vaccine
Cancer therapy via vaccineShiv Kumar
 
Basic principles of cancer immunotherapy
Basic principles of cancer immunotherapyBasic principles of cancer immunotherapy
Basic principles of cancer immunotherapyMohamed Abdulla
 
Immunotherapy Update in Oncology
Immunotherapy Update in OncologyImmunotherapy Update in Oncology
Immunotherapy Update in OncologyDee Chaudhary
 
Cancer vaccine from mice to humans
Cancer vaccine from mice to humansCancer vaccine from mice to humans
Cancer vaccine from mice to humansHoussein A Sater
 
Cancer immunotherapy nivedita shah msc.biotech- 13937
Cancer immunotherapy   nivedita shah  msc.biotech- 13937Cancer immunotherapy   nivedita shah  msc.biotech- 13937
Cancer immunotherapy nivedita shah msc.biotech- 13937eureka1
 
Cancer Immunotherapy
Cancer ImmunotherapyCancer Immunotherapy
Cancer ImmunotherapyManish Gupta
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapyNeha Patel
 
Principles of cancer immunotherapy
Principles of cancer immunotherapyPrinciples of cancer immunotherapy
Principles of cancer immunotherapyIhor Arkhypov
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapykhehkesha
 
Cancer Immunotherapy
Cancer ImmunotherapyCancer Immunotherapy
Cancer ImmunotherapyAsokan R
 
Cancer immunotherapy
Cancer immunotherapy Cancer immunotherapy
Cancer immunotherapy Kevin Lin
 
Tumor And Microenvironment
Tumor And MicroenvironmentTumor And Microenvironment
Tumor And Microenvironmentabhitux
 

Was ist angesagt? (20)

Immunotherapy for cancer
Immunotherapy for cancer Immunotherapy for cancer
Immunotherapy for cancer
 
Cancer immunotherapy different modes of action - astra zeneca - jordan
Cancer immunotherapy   different modes of action - astra zeneca - jordanCancer immunotherapy   different modes of action - astra zeneca - jordan
Cancer immunotherapy different modes of action - astra zeneca - jordan
 
Cancer therapy via vaccine
Cancer therapy via vaccineCancer therapy via vaccine
Cancer therapy via vaccine
 
Immunotherapy of Cancer I
Immunotherapy of Cancer IImmunotherapy of Cancer I
Immunotherapy of Cancer I
 
Basic principles of cancer immunotherapy
Basic principles of cancer immunotherapyBasic principles of cancer immunotherapy
Basic principles of cancer immunotherapy
 
Immunotherapy Update in Oncology
Immunotherapy Update in OncologyImmunotherapy Update in Oncology
Immunotherapy Update in Oncology
 
Cancer vaccine from mice to humans
Cancer vaccine from mice to humansCancer vaccine from mice to humans
Cancer vaccine from mice to humans
 
Cancer immunotherapy nivedita shah msc.biotech- 13937
Cancer immunotherapy   nivedita shah  msc.biotech- 13937Cancer immunotherapy   nivedita shah  msc.biotech- 13937
Cancer immunotherapy nivedita shah msc.biotech- 13937
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapy
 
Cancer Immunotherapy
Cancer ImmunotherapyCancer Immunotherapy
Cancer Immunotherapy
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapy
 
Principles of cancer immunotherapy
Principles of cancer immunotherapyPrinciples of cancer immunotherapy
Principles of cancer immunotherapy
 
Tumor Immunology and Cancer Immunotherapy
Tumor Immunology and Cancer ImmunotherapyTumor Immunology and Cancer Immunotherapy
Tumor Immunology and Cancer Immunotherapy
 
Cancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene TherapyCancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene Therapy
 
Cancer vaccine
Cancer vaccineCancer vaccine
Cancer vaccine
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapy
 
Cancer Immunotherapy
Cancer ImmunotherapyCancer Immunotherapy
Cancer Immunotherapy
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
 
Cancer immunotherapy
Cancer immunotherapy Cancer immunotherapy
Cancer immunotherapy
 
Tumor And Microenvironment
Tumor And MicroenvironmentTumor And Microenvironment
Tumor And Microenvironment
 

Ähnlich wie Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History of Failures

Global cancer vaccine market & clinical trial insight
Global cancer vaccine market & clinical trial insightGlobal cancer vaccine market & clinical trial insight
Global cancer vaccine market & clinical trial insightKuicK Research
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3ScottJordan
 
Vital Signs Edition #6
Vital Signs   Edition #6Vital Signs   Edition #6
Vital Signs Edition #6ScottJordan
 
Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
 
Galena presentation 8 feb 16
Galena presentation  8 feb 16Galena presentation  8 feb 16
Galena presentation 8 feb 16Galenabio
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentationoncolyticsinc
 
180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5targovax2017
 
Vital Signs Edition #5
Vital Signs   Edition #5Vital Signs   Edition #5
Vital Signs Edition #5ScottJordan
 
Ethical Dilemma On Randomized Clinical Trials
Ethical Dilemma On Randomized Clinical TrialsEthical Dilemma On Randomized Clinical Trials
Ethical Dilemma On Randomized Clinical TrialsAshley Lott
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentationoncolyticsinc
 
BioClonetics - Monoclonal Antibody HIV Therapy
BioClonetics - Monoclonal Antibody HIV TherapyBioClonetics - Monoclonal Antibody HIV Therapy
BioClonetics - Monoclonal Antibody HIV Therapyccotropia
 
Adc drugs to be launched in 2020
Adc drugs to be launched in 2020Adc drugs to be launched in 2020
Adc drugs to be launched in 2020DoriaFang
 
immunotherapeutics History, Classification and Humanization Antibody Therapy....
immunotherapeutics History, Classification and Humanization Antibody Therapy....immunotherapeutics History, Classification and Humanization Antibody Therapy....
immunotherapeutics History, Classification and Humanization Antibody Therapy....Sahil Nandal
 
WP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final editsWP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final editsChris Learn, Ph.D, PMP
 
Maslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-bloodMaslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-bloodSellasCorp
 
Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)celltrionh
 
Clinical trials and safety considerations
Clinical trials and safety considerationsClinical trials and safety considerations
Clinical trials and safety considerationsZahraa63902
 

Ähnlich wie Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History of Failures (20)

Global cancer vaccine market & clinical trial insight
Global cancer vaccine market & clinical trial insightGlobal cancer vaccine market & clinical trial insight
Global cancer vaccine market & clinical trial insight
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3
 
Vital Signs Edition #6
Vital Signs   Edition #6Vital Signs   Edition #6
Vital Signs Edition #6
 
Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015
 
Galena presentation 8 feb 16
Galena presentation  8 feb 16Galena presentation  8 feb 16
Galena presentation 8 feb 16
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentation
 
180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5
 
Vital Signs Edition #5
Vital Signs   Edition #5Vital Signs   Edition #5
Vital Signs Edition #5
 
Ethical Dilemma On Randomized Clinical Trials
Ethical Dilemma On Randomized Clinical TrialsEthical Dilemma On Randomized Clinical Trials
Ethical Dilemma On Randomized Clinical Trials
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentation
 
Vaccine101, Dynport Vaccine Company LLC
Vaccine101, Dynport Vaccine Company LLCVaccine101, Dynport Vaccine Company LLC
Vaccine101, Dynport Vaccine Company LLC
 
BioClonetics - Monoclonal Antibody HIV Therapy
BioClonetics - Monoclonal Antibody HIV TherapyBioClonetics - Monoclonal Antibody HIV Therapy
BioClonetics - Monoclonal Antibody HIV Therapy
 
Adc drugs to be launched in 2020
Adc drugs to be launched in 2020Adc drugs to be launched in 2020
Adc drugs to be launched in 2020
 
immunotherapeutics History, Classification and Humanization Antibody Therapy....
immunotherapeutics History, Classification and Humanization Antibody Therapy....immunotherapeutics History, Classification and Humanization Antibody Therapy....
immunotherapeutics History, Classification and Humanization Antibody Therapy....
 
Dendreon.Final
Dendreon.FinalDendreon.Final
Dendreon.Final
 
WP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final editsWP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final edits
 
Maslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-bloodMaslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-blood
 
Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)
 
Pham2018
Pham2018Pham2018
Pham2018
 
Clinical trials and safety considerations
Clinical trials and safety considerationsClinical trials and safety considerations
Clinical trials and safety considerations
 

Kürzlich hochgeladen

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 

Kürzlich hochgeladen (20)

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 

Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History of Failures

  • 1. Therapeutic Cancer Vaccines A Future of Possibilities Haunted by a History of Failures Preparedby2911Advisers
  • 2. Therapeutic CancerVaccines-The Genesis  Over a century ago, Dr.William B. Coley, a bone surgeon, developed a method of immunotherapy  Believing that bacterial toxins stimulated the immune system, he injected a cancer patient with live bacteria; the patient made a complete recovery1,2  Dr. Coley went on to develop a safe and effective mixture of bacteria for treating cancer patients known as Coley’s mixed bacterial toxins  Through the decades followingColey’s introduction of immunotherapy, many attempts have been made to develop and bring cancer vaccines to market  Success, however, has been elusive Prepared by 2911 Advisers 1American Cancer Society 2 www.cancerresearch.org/about/history
  • 3. Therapeutic CancerVaccines  Therapeutic cancer vaccines, orTCVs, as with the whole of immunotherapy, hold a tremendous amount of promise  Some of that promise has already been realized in several approved immunotherapeutics, but only oneTCV  The pipeline for biologics is robust  PhRMA reports over 900 biologics in development in 15 different therapeutic areas, targeting a wide range of indications1  Cancer vaccines comprise nearly 36% of all biologic vaccines in development in the report2 and 28% of all cancer biologics being developed  Preventative cancer vaccines are included in the report  These slides focus only onTCVs Prepared by 2911 Advisers 1 PhRMA 2013 Medicines in Development: Biologics 2Trials for 3 vaccines have been stopped and a product acquisition has lowered the reported number
  • 4. Therapeutic Cancer Vaccines Possibilities and Promises in Development Preparedby2911Advisers
  • 5. TCVs in Development  One hundredTCVs are included in this review  These include most of the vaccines in the PhRMA report, and those identified through searches on clinicaltrials.gov, the InternationalTrials Registry, and company pipelines  New and/or discontinued indications were identified during the searches of company pipelines  Trials conducted by the NCI and other agencies, research centers and universities are not included, unless the trial is being conducted on behalf of a company  A 2011 University of Michigan found that there were 231TCVs in clinical development1; a more recent report2 shows 196TCVs being developed Prepared by 2911 Advisers 1 HumVaccin. 2011 Nov;7(11):1124-9 2 Kaloroma
  • 6. A Snapshot  Among the 100TCVs, a total of 34 different cancer indications are targeted  Ten indications have received orphan designation, 6 received fast track designation, and 4 were designated both orphan and fast track  There are 12 specific types of vaccines, i.e. dendritic cell, among the 100 in development  Twenty-six of the vaccines are in Phase 3 clinical trials  Four of these trials have been completed, of which two missed their primary endpoints: Merck KGaA/Oncothyreon (NSCLC) and Kael-GemVax (pancreatic)  Seventy-three companies are represented Prepared by 2911 Advisers
  • 7. Targeted Indications andTypes ofTCVs Indication Number Prostate 16 Breast 15 Glioblastoma 14 NSCLC 12 Melanoma 12 Solid tumors 10 Hematological 10 Type Number Peptide 20 Genetically- modified 14 Dendritic 12 Cell (autologous/alloge nic) 12 mAB 9 Recombinant 8 Prepared by 2911 Advisers Other targeted cancers are renal, SCLC, sarcoma, endometrial, ovarian, colorectal,GI, pancreatic, bladder, head & neck, colon, urogenital, and mesothelioma Other types of vaccines include DNA, virus vector, virus replicon virus, antibody, bacterial and polyclonal antibody
  • 8. TCVs by Clinical Stage The vaccines in development are shown by their respective clinical stage in the table below. Note that none are in regulatory review Prepared by 2911 Advisers Stage Number Phase 0 3 Phase I 28 Phase II 34 Phase III 26 Phase I/II 31 Phase II/III 3 Clinical stage includes recruiting, ongoing, ongoing and recruiting, ongoing but not recruiting Phase 1, 2 or 3 ready and completed.Trials with an unknown status are not included.
  • 9. Companies DevelopingTCVs Activartis Biotech (1) Bioven Europe (1) Endocyte (1) Adamis Pharmaceuticals (1) Biovest International (1) Etubics (1) Aduro Biotech (5) B-MS/Medarex (1) Galena Biopharma (2) Advaxis (1) BN ImmunoTherapeutics (3) Gliknik (1) Agenus (3) Cancer Advances (1) GlobeImmune (3) AlphaVax (2) CelldexTherapeutics (2) Gradalis (1) Antigen Express (2) CGTherapeutics (1) Grupo Insud (1) ArgosTherapeutics (1) Colby Pharmaceuticals (2) GSK (3) AvaxTechnologies (2) Dendreon (2) Heat Biologics (1) Bayer (1) DCPrime (1) Hemispherex (1) Bellicum Pharmaceuticals (1) EMD Millipore (1) Immatics biotech (2) BioCancell Ltd (1) EMD/Oncothyreon (1) Immunicum AB (1)
  • 10. Companies DevelopingTCVs Immunitor (1) Merck/Vical (1) PsiOxus (1) ImmunoCellular (1) Mologen AG (1) Stemline Therapeutics (1) Immunocore (1) NewLink Genetics (3) Sunovion (1) ImmunoFrontier (1) Northwest Bio (1) Tapimmune (1) Immunotope (1) NovaRx (2) Transgene/Novartis (1) Immunovaccine (2) OncoPep (1) Tvax Biomedical (2) ImmunovativeTherapies (1) Oncothyreon (1) UbiVac (1) Inovio Pharmaceuticals (1) Onyvax (1) Vaccinogen (1) Kael-GemVax (1) Optimer Biotech (1) Vaxil Bio (1) MabVaxTherapeutics (6) PiqueTherapeutics (1) Vaximm GmbH (1) Mediolanum Farmaceutici (1) Polynoma (1) Memgen (1) Prima BioMed (1)
  • 11. Therapeutic Cancer Vaccines A History of Development Failures, but Paradigms are Changing Preparedby2911Advisers
  • 12. TCVs-Long on Promises…………. Cancer vaccines targeted by many as the ‘holy grail’ for tumors Promising CancerVaccineCould ShrinkTumors By 80 Percent Brain CancerVaccine Promising Prostate CancerVaccine Looks Promising in EarlyTrial Personalized Immunotherapy Shows Promise in Mantle Cell Lymphoma PANVAC for breast, ovarian cancer shows early promise Surgical Oncologist Presents Promising Data for Novel Pancreatic CancerVaccine CouldThis BeThe End Of Cancer? …scientists say vaccines could hold the key—not just to a cure but to wiping out cancer forever Therapeutic polyvalent vaccine shows promise against melanoma MUC1 peptide vaccines still show promise for lung cancer victims Prepared by 2911 Advisers Consider these headlines
  • 13. ………..But Short on Approvals  The preceding headlines come from press releases issued by companies either developingTCVs while some represent to failed TCVs  And whileTCVs and their promises continue to excite physicians, patients, investors, scientists and analysts  a speaker at ASCO 2013 reminded his audience that the promises of immunotherapy extend back at least 40 years, displaying the March 19, 1973 cover ofTime Magazine featuring noted immunologist Robert Good  Although new types ofTCVs are in clinical trials including, antigen, dendritic cell, vector-based, DNA and tumor cell and show positive results, Provenge remains the only FDA-approvedTCV and none are approved in the EU Prepared by 2911 Advisers
  • 14. Failure Is Not An Option  The path to approval is littered with failures; Phase 2 vaccines that have shown great promise fail in Phase 3; below are some examples Prepared by 2911 Advisers Biopharmaceutical companies with failed cancer vaccines Genzyme: Melan-A Genitope: MyVax Imclone: Mitumomab IDM Pharma: UVIDEM and COLLIDEM Titan Pharmaceuticals: CeaVac Therion: PANVAC-VF TeloVac: GV1001 CancerVax: Canvaxin Corixa: Melacine Oncothyreon/Merck KGaA: Stimuvax* Oxford Biomedica: TroVax Cell Genesys: GVAX prostate *Despite missing its primary Phase 3 endpoint for NSCLC, the companies decided to proceed with an ongoing late-phase trial in Asia and is weighing the options of starting a further study. A decision, partly dependent on the outcome of talks with regulators, is expected this year.
  • 15. Some Failures Get a Second Chance  PROSTVAC failed to demonstrate a reducedTTP for prostate cancer  Two years later, it was discovered that PROSTVAC had demonstrated a statistically significantOS; Bavarian Nordic licensed the drug, which is now in Phase 3  Aduro Biotech resurrected twoTCVs it acquired, one for metastatic pancreatic cancer, now in Phase 2, and the second for prostate cancer (preclinical) Prepared by 2911 Advisers
  • 16. Why DoTCVs Fail?  A recently published paper suggested that someTCV failures can be blamed on a self-sabotaging adjuvant1; instead of destroying tumors, T-cells accumulate at the vaccination site, with the miss-targeting due to incomplete Freund's adjuvant  Trial design: selection of clinical trial endpoints, disease stage, patient population, and trial duration2  A retrospective analysis of 23 completed or terminated P3 studies showed that 74% (17/23) failed to demonstrate significant efficacy in the primary endpoint, suggesting tumor burden may not be the only prognostic factor3  Considering the above, the current oncology drug development paradigm doesn’t fit Prepared by 2911 Advisers 1 Nature Medicine:Willem Overwijk,Assistant Professor, MD AndersonCancer Center 2 http://obroncology.com/documents/OBR_JAN10_CV.pdf 3 www.landesbioscience.com/journals/vaccines/article/23917/
  • 17. It’s Not a One-Size-Fits-All Development Paradigm Conventional Oncology Drug Development Paradigm, designed for cytotoxics Phase N (variable) Purpose 1 20 to 80 healthy volunteers, or patients (may or may not have target disease) Determine safety, dose range, MTD, DLT Characterize pK If mixed population, find target 2 100 to 300 patient volunteers with targeted disease Evaluate effectiveness, look for side effects. May provide estimate of effect size for Phase 3 Discuss continuation with regulatory authorities 3 500 to 1,000 patient volunteers Verify effectiveness, monitor adverse reactions from long- term use 4 Large number of patients Post-marketing surveillance Prepared by 2911 AdvisersModified from CheneyT. & Kaspar P. Overview of Clinical Research, 1996.
  • 18. The Conventional Paradigm Doesn’t Fit: TCVs Are Not Cytotoxics Prepared by 2911 Advisers General principles of oncology drug development Why these principles don’t adapt to cancer vaccines Increasing dose increases efficacy MTDs aren’t optimal doses; cancer vaccines usually have low toxicity; no proof for a linear dose-potency relationship PK is relevant for finding optimal dose Cancer vaccines aren’t metabolized; not evident that a MTD will be coincident with the optimal dose to reach the vaccine effect Objective responses (OR) predict clinical benefit OR is not a good predictor of survival Endpoints based on selected tumor size Tumors may progress prior to immune response and regression Mixed tumor trials for target selection Many cancer vaccines are designed to address only one tumor type Objective progression is considered a failure; drugs aren’t active if tumor is growing Cancer vaccines could be actives beyond disease progression; translating immune response into antitumor response takes time
  • 19. Changing the Paradigm  Over the course of a year, the CancerVaccineClinicalTrialWorking Group, comprised of more than 50 individuals from academia, the pharmaceutical and biotech industries, and regulatory bodies developed and proposed changes to the existing paradigm1  The Cancer Immunotherapy Consortium of the Cancer Research Institute, from 2004 to 2009, evaluated an immunotherapy-focused development paradigm, creating principles for redefining trial endpoints2  Other scientists, researchers, regulatory officials and academicians reviewed the current paradigm and proposed changes3 Prepared by 2911 Advisers 1The CancerVaccine ClinicalTrialWorking Group, J Immunother Jan 2006 2 JNCI J Natl Cancer Inst,Vol 102, Issue 18 Pp. 1388-1397 3 Cancer vaccines:Will we ever learn? Expert Review of AnticancerTherapy, January 2009,Vol. 9, no. 1, Pages 67-74
  • 20. Recommendations for a New Paradigm:The CancerVaccineClinicalTrialWorking Group Prepared by 2911 Advisers Phase of development Purpose Endpoints Proof-of-Principle -N>20 -Defined patient population with no end stage -No mandate to investigate exact mechanism of action disease -Safety database initiated -Establish immunogenicity, biologic activity, clinical activity -Use established and reproducible immune assays -Cohort design determines dose and schedule of vaccination -Impact of the vaccine on immune response or on investigated disease -Sequential samples for assays -No mandate to demonstrate clinical activity with conventional endpoints Phase 2 comparative randomized, powered for statistically significant difference between two arms in a well-defined population, a well-defined primary outcome measure (may be a surrogate) -Expansion of safety database -Establishment of efficacy -Flexibility of development, e.g. allow for sample size re- calculation, allow for modification of Phase 3 eligibility criteria -Validated surrogates or biomarkers as efficacy endpoints -Validation needs proof-of- correlation between outcome and biological marker in single-arm or randomized studies (prognostic factor), or -needs randomized trial showing that intervention-induced surrogate correlates with outcome (immune response) Phase 3 conventional trial -Data from Phase 3 component not to be pooled with Phase 2 data www.sitcancer.org/meetings/am05/workshop_presentations/workstream_2.pdf, not all recommendations included
  • 21. Recommendations for a New Paradigm: The Cancer Immunotherapy Consortium Prepared by 2911 Advisers Source: JNCI J Natl Cancer Inst,Vol 102, Issue 18 Pp. 1388-1397 Endpoint Cellular immune response Antitumor response Survival Challenges -Complex assays exist -Results are highly variable and not reproducible across trials -Assay procedures are not harmonized -Conventional and novel response patterns are observed -Translating immune response into antitumor response takes time -No systematic criteria to capture new response patterns exist -Time it takes to translate immune and antitumor response into a survival effect -Conventional statistical models don’t account for non-proportional hazards and delayed separation of curves Recommendations -Harmonized assay use through SOPs that accompany individual assay protocols -Identify relevant response patterns -Use systematic criteria (irRC*) to reproducibly capture new patterns -Employ statistical models that account for the delayed effect -Carefully consider use of early interim and futility analyses The core aspects of all recommendations are included in Guidance for Industry:ClinicalConsiderations forTherapeuticCancerVaccines US Dept. of Health and Human Services, FDA,CBER, October 2011 * immune-related response criteria
  • 22. Regulatory Comments and Considerations May or may not determine MTD (and that’s OK) Vaccine-specific toxicities as endpoint for early stage trials- clinical activity is secondary objective Explore continuation of vaccine after initial progression if Subject continues to meet eligibility criteria No clinical deterioration No curative salvage therapy exists Consider randomized Phase 2 trials PFS,TTP, DFS can’t be interpreted in single arm trials Single arm trials may lead to overly optimistic interpretation of effect size Phase 3 endpoints PFS is preferred overTTP OS remains the gold standard and may be the bestTCV endpoint as PFS has yet to be successful DFS in adjuvant setting US Regulatory Considerations forTherapeutic Cancer Vaccines Peter Bross, MD,Team Leader,Clinical Oncology, FDA CBER;2012 AACR Annual Meeting
  • 23. CBER: Going Beyond Comments and Considerations  CBER included the core aspects of a number of the recommendations made by theCancerVaccine ClinicalTrialWorking Group and the Cancer Immunotherapy Consortium in a 2011 guidance document1  Support of virology, molecular and tumor biology, and safety and efficacy immunology studies of gene transfer and tumor vaccines has begun2,3  Improved tools for clinical trial and design are being developed  The division is evaluating and implementing novel methods to improve reliability, sensitivity, and specificity of assays for product development and lot release  CBER acknowledges that endpoints based on tumor assessments4 may not be appropriate endpoints for a late phase clinical trial for a cancer vaccine Prepared by 2911 Advisers 1 Guidance for Industry:Clinical Considerations forTherapeuticCancerVaccines,Oct 2011 2 Nat Med 2013 Apr;19(4):452-7,Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Xu Z,Qiu Q,Tian J, Smith JS, Conenello GM, MoritaT, Byrnes AP 3 CBER Strategic Plan for Regulatory Science and Research FY 2012-2016; Draft 4 Guidance for Industry:ClinicalTrial Endpoints for the Approval of Cancer Drugs and Biologics; May 2007
  • 25. Selected Deals andTerms-FailedTCVs Licensee/Licensor Date Assets Terms Sanofi Aventis/Oxford Biomedica 03/07 TroVax, renal cancer; Phase 2 WW license; $38.6M upfront, $25.3M development milestone; total deal value $690M SanofiAventis/IDM Pharma 07/01 UVIDEM, melanoma Phase 2 WW license; up to $545M MerckSerono/Canva x 12/04 Canvaxin, melanoma License; $25M upfront, $12M in equity, up to $253M in milestones Takeda/CellGenesys 03/08 GVAX prostate, Phase 3 AcquiredWW rights; $50M upfront, up to $270M in milestones, tiered double-digit royalties on net sales in US, flat double-digit RoW
  • 26. Selected Deals andTerms-TCVs in Development Licensee/Licensor Date Assets Terms Aduro Biotech/BioSante Pharma 04/11 GVAX pancreas, prostate vaccines Phase 2 & Phase 3 License; milestones, royalties when commercialized 02/13 All GVAX vaccines; Phase 1, Phase 2 and Phase 3 Acquisition; $1M upfront, additional milestones & royalties when commercialized Merck/Vical 06/05 Non-viral gene delivery technology Exercised 3 options to licenseVical technology forTCVs; $3M upfront, milestones, royalties Accentia/Biovest 04/03 Biovax ID; Phase 3 $20M equity (81% stake) Pfizer/Celldex (Pfizer returned rights in 2010) 04/08 Peptide vaccine, glioma; Phase 2 WW license; $40M upfront, $10M equity, over $390M in milestones, royalties, fund development
  • 27. Selected Deals andTerms-TCVs in Development Licensee/Licensor Date Assets/Phase Terms Private investor/Argos Therapeutics 11/08 Dendritic cell vaccine; Phase 1/2 $35.2M Series C financing Merck KGaA/Biomira (nowOncothyreon) 05/01 Stimuvax & Theratope vaccines WW license; $33.5M in upfront and equity, share development costs, 50/50 sales split in US, Canada, royalties elsewhere 01.06 Stimuvax; Phase 3 Acquisition of full US rights; royalties and regulatory milestones 12/08 Manufacturing; Phase 3 License/acquisition; $13M to license mfg. rights and acquire mfg. assets for Stimuvax Novartis/Transgene 03/10 Genetically- modified vaccine; Phase 2 Option toWW rights; $10M upfront, additional $950M if option exercised
  • 28. PartneringTCVs in Development  There are 5 partnerships identified among the 73 companies in this review  B-MS/Medarex (B-MS has acquired Medarex)  Merck KgaA/Oncothyreon  Merck/Vical  Transgene/Novartis  GlobeImmune/Celgene (Celgene has an exclusive option to license all of GlobeImmune’s oncology programs)  A review of the partnering strategies of the remaining companies reveals at least 44 are or will be seeking a commercialization partner
  • 29. About 2911 Advisers 2911 Advisers is a Life Sciences consulting firm in Nashua, NH and is owned by Michael Sheckler, MBA.With a focus on oncology and pain management, he assists clients with business/strategy development, product & technological assessment, opportunity identification, market valuation, market/competitive analysis and negotiating licenses. He can be reached at 603 809-9936 or at michael.sheckler@gmail.com. Prepared by 2911 Advisers